TrialBMC cancer2024

Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.

Mohamed A Eltelbanei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.